MariTide (Maridebart Cafraglutide)
AMG 133 MariTide
An investigational antibody-peptide conjugate given subcutaneously once a month or less often, in Phase 3. It is not approved for any use.
- Half-life
- Not established
- Out of system
- —
- Route
- Subcutaneous
- Level
- Advanced
What MariTide (Maridebart Cafraglutide) is used for
- Monthly — or less frequent — dosing, against weekly for the rest of the class
- Up to ~20% mean weight loss at 52 weeks in Phase 2 without type 2 diabetes
- ~17% mean weight loss with type 2 diabetes, alongside up to -2.2% HbA1c
How it's typically used
Trial range: 140, 280 or 420 mg subcutaneously every four weeks, escalated per study protocol. Not approved — trial participation is the only route.
What to watch for
- Investigational; Phase 3 began in 2026 and it is not approved anywhere
- GI adverse events were common in Phase 2 — nausea, vomiting, constipation — and were reduced by slower escalation
- Not obtainable outside a clinical trial
- Phase 2 is 52 weeks; durability and long-term safety are still being collected
Common questions
- How is MariTide (Maridebart Cafraglutide) taken?
- MariTide (Maridebart Cafraglutide) is typically administered by the subcutaneous route. Trial range: 140, 280 or 420 mg subcutaneously every four weeks, escalated per study protocol. Not approved — trial participation is the only route.
- What are the risks of MariTide (Maridebart Cafraglutide)?
- Investigational; Phase 3 began in 2026 and it is not approved anywhere GI adverse events were common in Phase 2 — nausea, vomiting, constipation — and were reduced by slower escalation Not obtainable outside a clinical trial Phase 2 is 52 weeks; durability and long-term safety are still being collected
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.